https://www.selleckchem.com/pr....oducts/dabrafenib-gs
08, 95% CI 1.27-3.42, P=0.004), substance-related disorders (OR 2.84, 95% CI 2.33-3.46, P0.00001), and alcohol abuse (OR 1.94, 95% CI 1.43-2.64, P0.0001). For dermatologists treating patients with HS, screening for these comorbidities, psychiatric referral and adequately managing pain will improve the overall wellbeing of patients. For dermatologists treating patients with HS, screening for these comorbidities, psychiatric referral and adequately managing pain will improve the overall wellbeing of patients. Radiomi
Like
Comment
Share
